US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BiBBInstrument’s CEO to BioStock: “Distributors are contacting us”

BiBBInstruments recently released its report for the third quarter and at the same time announced a rights issue of approximately SEK 36.5 million. BioStock contacted CEO Fredrik Lindblad to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/bibbinstruments-ceo-distributors-are-contacting-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Impressive US Clinical Case Series presented at ACG 2024 in Philadelphia

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that a recently published clinical case series in the U.S. has been presented at a poster session at the ACG 2024 in Philadelphia, USA. The study outcome demonstrated 100 % diagnostic accuracy after a single needle puncture, and the authors conclude that the EndoDrill[®] GI has great potential to be implemented as a first option in any scenario where endoscopic ultrasound (EUS)-guided tissue acquisition is

BiBB receives an Intention to Grant for EndoDrill patent in China

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the China National Intellectual Property Administration (CNIPA). The notice means that CNIPA intends to approve a patent application for EndoDrill[®] in the first patent family in China. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.BiBB has received an Intention to Grant from CNIPA regarding the

New Peer-Reviewed Clinical Case Series in the U.S. Shows 100% Diagnostic Accuracy with EndoDrill GI

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first eight patient cases using EndoDrill[®] GI in the U.S. have been scientifically published in Endoscopy International Open. Biopsies were sampled in the pancreas, esophagus, stomach, and small intestine. In all cases EndoDrill[® ]GI obtained 100% diagnostic accuracy after only one needle pass. In four patients, both EndoDrill[® ]GI and conventional needles were used to sample the same lesion, in

BioStock: BiBB comments on the growing interest in EndoDrill GI

Intensive work is underway to get EndoDrill GI out to European and US clinics. BiBBInstruments recently participated in the seventh edition of the Nordic EUS Meeting in Copenhagen, where the biopsy instrument aroused great interest. BioStock has spoken to CEO Fredrik Lindblad to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/bibb-comments-on-the-growing-interest-in-endodrill-gi/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

EndoDrill GI sparks interest at the 7th Nordic EUS Meeting in Copenhagen

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the Company, for the first time, has exhibited a commercial version of EndoDrill[®] GI at the 7th Nordic EUS Meeting in Copenhagen. The meeting was aimed at BiBB’s target group, EUS endoscopists, and several participants expressed interest in the EndoDrill[®] technology. Demonstrations of the EndoDrill[®] GI system resulted in explicit requests to clinically evaluate the product from several new hospitals

BiBB’s CEO to BioStock: “Zagreb confirms good samples and short learning curve”

The clinical introduction is in full swing for BiBBInstruments. The company’s first electric-driven biopsy instrument, EndoDrill GI, continues to impress with high-quality tissue samples, most recently at an introduction of EndoDrill GI at the University Hospital in Zagreb. Meanwhile, the European Patent Office announced the intention to grant the patent application for the EndoDrill technology. BioStock spoke to BiBB’s CEO Fredrik Lindblad to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/bibbs-ceo-zagreb-confirms-

BiBB receives an Intention to Grant for EndoDrill patent in Europe

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the European Patent Office (EPO). The notice means that the EPO intends to approve a divisional patent application (first patent family) in Europe for EndoDrill[®]. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.BIBB has received an Intention to Grant from the EPO regarding the approval of the patent

Successful introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the University Hospital Center Sestre Milosrdnice in Zagreb, Croatia, has started a clinical evaluation with EndoDrill[®] GI. This makes the hospital the first in southern Europe to test EndoDrill[®] GI. Dr. Tajana Pavic, Head of Interventional Gastroenterology Unit, performed the patient cases.The EndoDrill[®] GI instrument provided high-quality core tissue biopsies in all four patient cases, including three solid

BioStock: BiBBInstruments’ technology gets nod in medical journal

The interest in Swedish medtech BiBBInstruments’ biopsy instrument EndoDrill is increasing as doctors evaluate it in the clinic, being called a “game-changer” within endoscopic ultrasound. Recently, the technology was also featured in a South American medical journal Revista de Gastroenterología del Perú, penned by leading specialist in the field, Dr Antonio Mendoza Ladd.Read the article at biostock.se: BiBBInstruments’ technology gets nod in medical journal - BioStock This is a press release

EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of EndoDrill[®], the world's first market-cleared motorized endoscopic core biopsy instrument, informs that EndoDrill[®] is recognized as a promising new EUS product on the editorial page of the South American medical journal Revista de Gastroenterología del Perú."It is encouraging that EndoDrill[®] is recognized as a promising new EUS instrument in an editorial that describes the future of endoscopic ultrasound. In addition, by an endoscopist who has recently tested the product clinically”, says Dr Charles Walther,

BioStock: Interest in BiBBInstruments’ EndoDrill GI continues to increase

The world's first market-cleared electric-driven biopsy instrument for endoscopy, EndoDrill GI, continues its track record of successful clinical evaluations. The device has received high praise from physicians at the University Hospital in Örebro and Haukeland University Hospital in Bergen, Norway. –  We notice that the interest in EndoDrill GI is gradually increasing as we initiate evaluations at new hospitals and participate in congresses, says Fredrik Lindblad, CEO at BiBB.Read the article at biostock.se: Interest in BiBBInstruments’ EndoDrill GI continues to increase - BioStock (

BiBBInstruments AB carries out a directed share issue of SEK 10.0 million

The Board of Directors of the cancer diagnostics company BiBBInstruments AB (publ) ("BiBB" or the "Company") has, based on the authorization granted by the Annual General Meeting on 14 June 2023, resolved to carry out a directed share issue of approximately SEK 10.0 million directed to existing major shareholders. Existing owners include Tibia Konsult, Swedencare Entrepreneurs, the Aktia Nordic Micro Cap fund, and Herenco Group owner Lovisa Hamrin. The net proceeds will primarily be used for continued clinical evaluation of EndoDrill[®] GI in the USA and Europe, as well as for preparations

Successful case studies with EndoDrill GI continue in Norway and Sweden

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, informs that clinical evaluation with EndoDrill[®] GI has started at two additional hospitals in Scandinavia. Several patient cases have been successfully performed at Haukeland University Hospital in Bergen, Norway, as well as at the University Hospital in Örebro. This means that EndoDrill[®] GI is now being evaluated in Sweden (Karolinska University Hospital and Örebro University Hospital), Norway (Haukeland

BioStock: EndoDrill seen as promising new EUS technology

BiBBInstruments’ endoscopic ultrasound instrument EndoDrill GI was recognised as a “New Kid on the Block” at the ESGE Days conference, indicating its emergence as a promising technology in the EUS field, challenging traditional methods of endoscopic tissue sampling. BioStock spoke with BiBB’s CEO Fredrik Lindblad to get his reaction to the conference.Read the article at biostock.se: EndoDrill seen as promising new EUS technology - BioStock This is a press release from BioStock - Connecting Innovation &

EndoDrill presented as New Kid on the Block at ESGE Days

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, informs about the international endoscopy congress in Berlin, ESGE Days, where EndoDrill[®] GI was named “New Kid on the Block”. The recognition was made at the session called “EUS Novelties in EUS Tissue Acquisition", led by Dr. Livia Archibugi from IRCCS San Raffaele Hospital in Milano, who referred to BiBB’s proming published data on EndoDrill[®] GI. At the same congress, BiBB's users from Sweden and the US had a

BiBB receives patent approval for EndoDrill in India

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces today that the Indian Patent Office has granted the first patent for EndoDrill[®]. The patent provides broad protection of the EndoDrill[®] system until October 2039.The approved Indian patent 532933 originates from the patent application IN202127017788 from patent family 1 and protects the EndoDrill[®] product series, the world's first market-cleared electric-driven biopsy instrument for endoscopy. BiBB has

Successful clinical pilot study with EndoDrill GI published in peer reviewed scientific journal

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the pilot study EDMX01 with EndoDrill[®] GI has been published in the peer reviewed Scandinavian Journal of Gastroenterology. The study results show 100 percent diagnostic accuracy when sampling with EndoDrill[®] GI and superseded samples taken in the same tumors with a leading standard biopsy instrument. The authors concluded that the EndoDrill[®] device was safe and easy to use, could obtain true core

BioStock: BiBB’s CEO - “Patient cases fortify our confidence in EndoDrill”

BiBBInstruments' cancer biopsy device, EndoDrill, has earned high praise from physicians who conducted the first clinical cases at Karolinska University Hospital in Stockholm, Sweden. This positive feedback follows the endorsement of EndoDrill as a "game-changer" in endoscopic ultrasound sampling by the Medical Director of Endoscopy at UC Davis in the US. BioStock spoke with BiBB’s CEO Fredrik Lindblad to learn more.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bibbs-ceo-patient-cases-fortify-our-confidence-in-endodrill/This is a press release from BioStock -

First clinical cases with EndoDrill GI successfully performed at Karolinska University Hospital in Sweden

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue acquisition procedures with EndoDrill[®] GI at Karolinska University Hospital in Stockholm have been successfully performed. BiBB is now planning to initiate more evaluations at a series of Scandinavian hospitals.In February, BiBB announced that the entire EndoDrill[®] product portfolio had received CE certification in accordance with MDR, i.e. market approval for the European

BioStock: BiBBInstruments expands patent protection to Japan

BiBBInstruments’ electric-driven biopsy instrument for advanced endoscopy, EndoDrill, has been market cleared in Europe and the US. The Swedish medtech is clearly aiming to expand its horizons as it has announced receiving a Decision to Grant from the Japanese Patent Office for the EndoDrill technology. BioStock reached out to CEO Fredrik Lindblad for a comment.Read the full interview with Fredrik Lindblad at biostock.se: https://www.biostock.se/en/2024/02/bibbinstruments-expands-patent-protection-to-japan/ This is a press release from BioStock - Connecting Innovation & Capital. https:

Japanese Patent Office Issues Decision to Grant Patent for EndoDrill Technology

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven endoscopic core biopsy instrument, announces that the Company has received a Decision to Grant from the Japan Patent Office (JPO). This means that JPO has decided to approve the Company's first patent application in Japan for EndoDrill[®]. A few additional formal steps will follow before a patent is finally issued, after which the granted patent will be valid until October 2039.BIBB has received a Decision to Grant from the JPO for its patent

UC Davis Health reports positive clinical experiences with EndoDrill GI

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven endoscopic core biopsy instrument, announces that clinical partner UC Davis Health has published an article on its website sharing positive experiences from the first clinical cases with EndoDrill® GI in the USA. Among other things, it is mentioned that EndoDrill[®] GI enables more accurate cancer diagnoses leading to improved treatment for patients, which can contribute to better patient outcomes.At the end of January, as previously communicated,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe